Component

Piperine

Piperine. Species, exposure and limitations are retained in each linked claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Piperine and capsaicin both stimulated TRPV1-dependent calcium responses in human PC-3 cells and both showed reduced responses on second exposure.

    Piperine → Capsaicin source_derived_draftungraded
    Experimental context and source evidence
    dose
    Capsaicin or piperine concentration-response; second exposure; SB366791 control
    duration
    Acute sequential exposure
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Human PC-3 cells expressing TRPV1
    limitations
    Comparable assay behavior does not establish equivalent potency, oral exposure, or benefit in humans.
    nutrient_topic
    Capsaicin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Capsaicin
    organism
    Human PC-3 cells expressing TRPV1
    plain_language
    Piperine and capsaicin both stimulated TRPV1-dependent calcium responses in human PC-3 cells and both showed reduced responses on second exposure.
    primary_references
    Pharmacodynamics of TRPV1 agonists in a bioassay using human PC-3 cells. (2014). https://pubmed.ncbi.nlm.nih.gov/24688365/ DOI: 10.1155/2014/184526
    route
    In vitro
    tissue
    Fluo-4 calcium-response bioassay

    Capsaicin: mechanism of action and interactions (2026-09-20) · lines 110–119

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human PC-3 cells expressing TRPV1 · source_derived_draft · unverified_draft

    ## capsaicin-piperine-shared-trpv1 Piperine and capsaicin both stimulated TRPV1-dependent calcium responses in human PC-3 cells and both showed reduced responses on second exposure. Model/species: Human PC-3 cells expressing TRPV1 Tissue/system: Fluo-4 calcium-response bioassay Exposure: Capsaicin or piperine concentration-response; second exposure; SB366791 control Route: In vitro Duration: Acute sequential exposure Limits: Comparable assay behavior does not establish equivalent potency, oral exposure, or benefit in humans. Primary reference: Pharmacodynamics of TRPV1 agonists in a bioassay using human PC-3 cells. (2014). https://pubmed.ncbi.nlm.nih.gov/24688365/ DOI: 10.1155/2014/184526 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  2. Piperine inhibited recombinant CYP3A4 more potently than CYP3A5.

    Piperine → Human cytochrome P450 3A4 source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/18480186.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1155ca38a767b3c3fa7bd494d0ad5590eed70a47812b7a6f3d977b43aa8a922", "start_char": 0, "end_char": 1788, "text_sha256": "c1155ca38a767b3c3fa7bd494d0ad5590eed70a47812b7a6f3d977b43aa8a922"}
    experimental_model
    Human microsomal/cytosolic and recombinant enzyme inhibition assays
    exposure
    Curcuminoid mixture, purified curcuminoids and piperine; micromolar concentrations
    limitations
    In-vitro inhibition does not automatically predict human drug levels. Extract, isolated curcumin and piperine are separate interventions.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Human enzyme systems
    plain_language
    The added absorption enhancer has its own enzyme effects.
    primary_references
    [curcumin-p18480186] Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. (2008). https://pubmed.ncbi.nlm.nih.gov/18480186/ DOI: 10.1124/dmd.108.020552
    tissue_or_cell_type
    Drug metabolism assays

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 905–916

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human microsomal/cytosolic and recombinant enzyme inhibition assays · source_derived_draft · unverified_draft

    ### curcumin-piperine-cyp3a4 Piperine inhibited recombinant CYP3A4 more potently than CYP3A5. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The added absorption enhancer has its own enzyme effects. organism: Human enzyme systems tissue_or_cell_type: Drug metabolism assays experimental_model: Human microsomal/cytosolic and recombinant enzyme inhibition assays limitations: In-vitro inhibition does not automatically predict human drug levels. Extract, isolated curcumin and piperine are separate interventions. exposure: Curcuminoid mixture, purified curcuminoids and piperine; micromolar concentrations evidence_span: {"source_cache": "artifacts/curcumin-research/18480186.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1155ca38a767b3c3fa7bd494d0ad5590eed70a47812b7a6f3d977b43aa8a922", "start_char": 0, "end_char": 1788, "text_sha256": "c1155ca38a767b3c3fa7bd494d0ad5590eed70a47812b7a6f3d977b43aa8a922"} [curcumin-p18480186] Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. (2008). https://pubmed.ncbi.nlm.nih.gov/18480186/ DOI: 10.1124/dmd.108.020552
    Complete structured claim and evidence

  3. Adding piperine increased measured curcumin exposure in this human comparison; the study reported a 2000% bioavailability increase.

    Piperine → Measured human circulating curcumin exposure, analytical fraction specified source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/9619120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e0eb4e2d68139e3b863853c46e30e52ad3bd67eaed1e6c4bbdefb278af10ee0b", "start_char": 0, "end_char": 1316, "text_sha256": "e0eb4e2d68139e3b863853c46e30e52ad3bd67eaed1e6c4bbdefb278af10ee0b"}
    experimental_model
    Human single-dose pharmacokinetic comparison; separate rat experiments
    exposure
    2 g curcumin with or without 20 mg piperine
    limitations
    Small older formulation-specific experiment. The reported 2000% increase is not a universal multiplier, therapeutic benefit or proof of long-term safety.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Homo sapiens for the recorded claim
    plain_language
    Piperine changed exposure in this particular experiment.
    primary_references
    [curcumin-p9619120] Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. (1998). https://pubmed.ncbi.nlm.nih.gov/9619120/ DOI: 10.1055/s-2006-957450
    tissue_or_cell_type
    Serum

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 268–279

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human single-dose pharmacokinetic comparison; separate rat experiments · source_derived_draft · unverified_draft

    ### curcumin-piperine-exposure Adding piperine increased measured curcumin exposure in this human comparison; the study reported a 2000% bioavailability increase. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Piperine changed exposure in this particular experiment. organism: Homo sapiens for the recorded claim tissue_or_cell_type: Serum experimental_model: Human single-dose pharmacokinetic comparison; separate rat experiments limitations: Small older formulation-specific experiment. The reported 2000% increase is not a universal multiplier, therapeutic benefit or proof of long-term safety. exposure: 2 g curcumin with or without 20 mg piperine evidence_span: {"source_cache": "artifacts/curcumin-research/9619120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e0eb4e2d68139e3b863853c46e30e52ad3bd67eaed1e6c4bbdefb278af10ee0b", "start_char": 0, "end_char": 1316, "text_sha256": "e0eb4e2d68139e3b863853c46e30e52ad3bd67eaed1e6c4bbdefb278af10ee0b"} [curcumin-p9619120] Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. (1998). https://pubmed.ncbi.nlm.nih.gov/9619120/ DOI: 10.1055/s-2006-957450
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02.

    Curcumin plus piperine regimen → Human endoxifen plasma exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"}
    experimental_model
    Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients
    exposure
    Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day
    limitations
    Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Homo sapiens
    plain_language
    The combination reduced exposure to tamoxifen's active metabolite.
    primary_references
    [curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
    tissue_or_cell_type
    Plasma drug and metabolite AUC

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 970–981

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients · source_derived_draft · unverified_draft

    ### curcumin-endoxifen-combination Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combination reduced exposure to tamoxifen's active metabolite. organism: Homo sapiens tissue_or_cell_type: Plasma drug and metabolite AUC experimental_model: Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients limitations: Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established. exposure: Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day evidence_span: {"source_cache": "artifacts/curcumin-research/30909366.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527", "start_char": 0, "end_char": 1407, "text_sha256": "43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527"} [curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards